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FIRST CLINICAL CASE IN EMERGING COUNTRYFatal Chromobacterium violaceum bacteraemia in rural Bandundu,
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of Public Health, Institute of Tropical Medicine, Antwerp and 5) Department of Microbiology and Immunology, University of Leuven, Leuven, BelgiumAbstractWe describe the ﬁrst case of bacteraemia caused by Chromobacterium violaceum in the Democratic Republic of the Congo. This diagnosis was
made in an apparently healthy adult who was admitted to a rural hospital of the province of Bandundu with severe community-acquired
sepsis. The patient developed multi-organ failure and died; to our knowledge, this is the ﬁrst reported fatal case in an adult in Africa.
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E. Bottieau and D. Mukendi contributed equally to the manuscriptIntroductionChromobacterium violaceum is a Gram-negative bacillus present
in tropical and subtropical soil and stagnant water. Approxi-
mately 150 cases of human infection have been published since
its ﬁrst description in Malaysia in 1927 [1,2]. Infection with this
organism often presents as severe, frequently fatal, bacteraemia,
which is typically observed in infants and children, sometimes
with underlying conditions such as chronic granulomatous
disease or glucose-6-phosphate dehydrogenase deﬁciency. Most
recent reports have come from southern Asia [3–6] and, to a
lesser extent, from South America [7]. To our knowledge, only
four observations have been published from Africa: two cases
of bacteraemia in adults, in Nigeria [8] and in South Africa [9],
the latter in a patient with leukaemia; a cluster of nosocomial
bacteraemia in a neonatal unit in Nigeria [10]; and a child inNew Microbes and New Infections © 2014 The Authors. Published by Els
This is an open access artiSenegal with severe diarrhoea and C. violaceum recovered from
a stool sample [11]. The nosocomial outbreak in Nigerian
newborns had a 50% case-fatality rate, but both adult cases and
the Senegalese child reportedly survived. We report here a
case of fatal C. violaceum bacteraemia in an adult in the province
of Bandundu, Democratic Republic of the Congo (DRC). The
case was observed during a clinical study investigating the ae-
tiologies of neurological disorders in rural Africa, conducted by
the Neglected Infectious Diseases Diagnostics (NIDIAG) con-
sortium (ClinicalTrials.Gov; identiﬁer NCT01589289).Case reportIn January 2013, a 30-year-old Congolese man was admitted for
acutely altered consciousness to the Hôpital Général de
Référence of Mosango, a poorly equipped rural hospital of
Bandundu, DRC. The patient was a trader with no medical
history who brought agricultural products from remote ﬁelds
to village markets. Three days before admission, he had
developed abrupt fever with cough, thoracic pain, and dysp-
noea, followed by abdominal pain, vomiting, diarrhoea and
ﬁnally, confusion, and did not respond to empirical antimalarial
treatment (artesunate–amodiaquine).New Microbe and New Infect 2015; 3: 21–23
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FIG. 1. Violet–black pigmentation of the Chromobacterium violaceum
isolate on sheep blood agar, after incubation at 37°C for 24 h.
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respond to simple questions and orders (Glasgow Coma Scale:
13/15). He had neck stiffness and moderate dehydration. His
temperature was 39°C, his pulse rate was 92/min, his respira-
tory rate was 28/min, and his blood pressure was 120/
90 mmHg. Crackles were heard over both lungs at auscultation,
and the abdomen was diffusely painful but depressible on
palpation. There was no jaundice and no skin lesion. The hae-
moglobin level was 12 g/dL (HemoCue HB 301 System;
HemoCue AB, Ängelholm, Sweden). White blood cell count
and blood chemistry were not determined, owing to temporary
breakdown of the respective devices. Chest X-rays revealed
bilateral patchy inﬁltrations. Abdominal ultrasonography did not
provide any relevant information. Malaria rapid diagnostic tests,
i.e. Pf-pLDH/Pan-pLDH (CareStart Malaria pLDH (Pf/PAN);
Access Bio Somerset, New York, NY, USA) and Pf-HRP2/Pan-
pLDH (SD Bioline FK60; Standard Diagnostics, Hagal-Dong,
Korea), both gave negative results. The programme human
immunodeﬁciency virus (HIV) rapid diagnostic test (Determine
HIV1-2; Alere Health, Waltham, MA, USA) and Rapid Plasma
Reagin for syphilis (BD Macro-Vue RPR Card Tests; Beckon
Dickinson and Company, Sparks, NV, USA) both gave negative
results. Microscopic examination of the cerebrospinal ﬂuid
(CSF) revealed a white blood cell count of 1/μL. No urine or
sputum could be immediately obtained, and no culture facilities
were available on site. Ceftriaxone and gentamicin were
empirically initiated together with crystalloid and oxygen
administration for acute sepsis. Approximately 16 h after
admission, the patient became tachypnoeic (respiratory rate of
36/min) and tachycardic (heart rate of 116/min), and developed
shock (blood pressure of 85/55 mmHg) that was non-
responsive to ﬂuid challenge. Mechanical ventilation and
inotropic agents were not available. The patient died 2 h later.
No autopsy was performed.
In line with the study protocol, blood was sampled on
admission (2 × 10 mL from two separate venipunctures) and
inoculated in aerobic blood culture vials (BacT/ALERT FA;
BioMérieux, Marcy-L’Etoile, France); CSF was inoculated in
paediatric blood culture bottles (BacT/ALERT PF, 4 mL). All
samples were shipped at room temperature to the Institut
National de Recherche Biomédicale, Kinshasa (8 h by road; only
one transport daily). Upon arrival, the growth indicator of the
blood and CSF culture isolates had turned positive. Gram
staining of both blood and CSF samples revealed Gram-negative
rods that, on subculture, had outstanding violet–black
pigmentation (Fig. 1). On Kligler-Iron Agar (Oxoid, Basingstoke,
UK), the organism fermented glucose. It was identiﬁed as C.
violaceum by API20 NE V7.0 (BioMérieux; proﬁle 1152554, very
good identiﬁcation) and later by the MicroScan (Biotype
40002007, Combo 42 panel; Siemens Healthcare Diagnostics,New Microbes and New Infections © 2014 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceDeerﬁeld, IL, USA). Antibiotic susceptibility testing (Combo 42)
interpreted according to CLSI M45 [12] revealed resistance to
β-lactam antibiotics (ampicillin, amoxycillin–clavulanic acid,
cefazolin, cefotaxime, and ceftazidime), susceptibility to ﬂuo-
roquinolone antibiotics (ciproﬂoxacin and levoﬂoxacin),
trimethoprim–sulphamethoxazole, and meropenem, and sus-
ceptibility and intermediate resistance to gentamicin and ami-
kacin (MICs of 4 mg/L and 32 mg/L, respectively).DiscussionFatal bacteraemia caused by C. violaceum has not been reported
in African adults. The large majority of the 106 cases analysed in
a recent systematic review had been diagnosed in the Americas
and southern Asia [2]. Usually, infection occurs through skin or
respiratory system exposure to stagnant water, and tends to
disseminate in a fulminant way, with a case-fatality rate
exceeding 50%. In the present patient, and similarly to other
observations [2,6], the family denied unusual exposure to wa-
ter, such as swimming or near-drowning. There were no skin
lesions suspected of being contaminated by soil [1,3,4]. The
patient initially presented with community-acquired sepsis of
uncertain origin [2], making the aetiological diagnosis almost
impossible, as laboratory and imaging data were not available.
Multi-organ failure (bilateral pneumonia, encephalitis, and
shock) rapidly developed, with an adverse outcome in this
deprived setting. Although the diagnostic exploration of the
case was seriously limited by the lack of facilities on site, theEuropean Society of Clinical Microbiology and Infectious Diseases, NMNI, 3, 21–23.
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blood and CSF cultures in the research laboratory of Kinshasa a
few days after the patient’s death. It was also not possible to
further assess the patient for predisposing conditions, but he
has been always been reportedly in good health, and the
negative HIV test result had ruled out an underlying HIV
infection.
Upon admission, typhoid fever, severe pneumonia and even
meningitis were considered, and ceftriaxone was ﬁnally
preferred over ciproﬂoxacin, although, in retrospect, the latter
could have been more beneﬁcial. The antimicrobial suscepti-
bility of C. violaceum was in line with that observed elsewhere,
with broad resistance to β-lactams that may have played a role
in the adverse outcome [2]. Multidrug resistance of bacteria
commonly involved in community-acquired infections is being
increasingly reported in Central Africa [13], including, for
example, decreased ﬂuoroquinolone susceptibility of Salmonella
Typhi in the DRC [14]. Empirical antibiotherapy covering the
whole spectrum of common and less common bacterial aeti-
ologies of community-acquired sepsis is therefore becoming
extremely challenging in such settings with limited therapeutic
options. The present case illustrates the need for microbio-
logical surveillance also at the peripheral level in remote African
settings, as multiresistance is emerging and unusual pathogens
may also be recovered. Coordinated research efforts should be
relentlessly expanded to comprehensively document the aeti-
ologies of febrile illnesses in the most neglected tropical pop-
ulations [15].Transparency declarationThis work was supported by a grant agreement 260260 from
the European Commission under the Health Cooperation
Work Programme of the 7th Framework Programme (FP7) to
the NIDIAG consortium (www.nidiag.org). All authors declare
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